Research programme: haemophilia therapeutics - Baxter/GenOdyssee

Drug Profile

Research programme: haemophilia therapeutics - Baxter/GenOdyssee

Latest Information Update: 01 Apr 2011

Price : $50

At a glance

  • Originator Baxter International; GenOdyssee
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Haemophilia

Most Recent Events

  • 26 Oct 2006 Preclinical trials in Haemophilia in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top